AeroLeads people directory · profile
Ariane Tom, Phd Email & Phone Number
Founder and Managing Director
at
Kaleida Capital
1 work email found
@kaleidacapital.com
1 phone found area 888
LinkedIn matched
✓ Verified Jun 2026
4 data sources
Profile completeness 100%
Current company
Role
Founder and Managing Director
Location
San Diego, California, United States
Company size
Who is Ariane Tom, Phd? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Ariane Tom, Phd is listed as Founder and Managing Director at Kaleida Capital, a company with 2 employees, based in San Diego, California, United States. AeroLeads shows a work email signal at kaleidacapital.com, phone signal with area code 888, and a matched LinkedIn profile for Ariane Tom, Phd.
Ariane Tom, Phd previously worked as Founder & Managing Director at Kaleida Capital and Investor at Anthropic. Ariane Tom, Phd holds Doctor Of Philosophy (Ph.D.), Bioengineering from Stanford University.
Company email context
Email format at Kaleida Capital
This section adds company-level context without repeating Ariane Tom, Phd's masked contact details.
{first}@kaleidacapital.com
89% confidence
AeroLeads found 1 current-domain work email signal for Ariane Tom, Phd. Compare company email patterns before reaching out.
Profile bio
About Ariane Tom, Phd
Dr. Ariane Tom is Founder & Managing Director of Kaleida Capital, investing in neurotech & the future of computation. Throughout her academic career at Stanford, Ariane spearheaded research programs in neural interfaces with applications in brain-mapping, prosthetics, drug delivery, and neuromodulation. She is a published co-author in top-tier research journals Science Magazine and Nature Portfolio, collaborating across disciplines with luminaries Karl Deisseroth (optogenetics & CLARITY), Zhenan Bao (electronic skin), and Sergiu Pasca (organoids). Beyond the bench, she has applied over a decade of research insight to venture capital, patent law, and public policy, cultivating a top-performing investment track record by identifying and backing technologies of multiple Nobel Laureates. She has served the Boards of several companies spanning neuroimaging, cancer diagnostics, drug discovery, and immunotherapy. Today, Ariane is a prominent voice for neurotechnology innovation and is a frequent speaker at events where she discusses neurotechnology development and investment landscape. Ariane holds a B.S. in Materials Science & Engineering, an M.S. in Bioengineering, and a Ph.D. in Bioengineering, all from Stanford University.
Listed skills include Biotechnology, Nanomaterials, Chemical Engineering, Bioelectronics, and 19 others.
Current workplace
Ariane Tom, Phd's current company
Company context helps verify the profile and gives searchers a useful next step.
Kaleida Capital
19 roles · 21 years
Ariane Tom, Phd work experience
A career timeline built from the work history available for this profile.
Founder & Managing Director
CurrentKaleida Capital is an early stage venture fund investing in neurotech & the future of computation.Speaking Engagements: “AI in Healthcare”- WIB at BIO International Convention 2024"Bioconvergence - Opportunity at the Intersection". LSI Emerging Medtech Summit, USA 2024."Early-Stage Neurotech Investment". North American Neuromodulation Society Annual.
May 2022 - Present
Investor
CurrentMaking AI systems you can rely on - Anthropic (developer of Claude) is a Public Benefit Corporation, whose purpose is the responsible development and maintenance of advanced AI for the long-term benefit of humanity.
Jun 2024 - Present
Lead Investor & Board Observer
Current
Manifest Technologies
Manifest Technologies is revolutionizing psychiatric drug development through its AI-powered precision neuroscience and computational neuroimaging platform.
Aug 2023 - Present
Member | Milken Institute Young Leaders Circle
CurrentThe YLC is a group of 300 intellectually curious, motivated and philanthropic young professionals from a range of industries around the world who support the Milken Institute and its mission.
Feb 2024 - Present
Advisor | Mental Health Startup Accelerator
CurrentThe One Mind Accelerator backs visionary founders of early-stage startups with a $100,000 investment and 10 weeks of intensive programming to build category-defining companies that improve the lives of people living with mental illness.For 2023 cohort, referred 3 of 11 participating companies from Kaleida pipeline: *Cereteype Neuromedicine: advanced.
Jan 2023 - Present
Industry Advisor | Venture Capital
CurrentKeynote Speaker: “Navigating Mentorship as a Biotech Entrepreneur”. Nucleate San Diego -Activator Program Kickoff Event, 2023.
Nov 2021 - Present
Committee Member | Capital Development & Partnering
CurrentA group of board-level directors, investors, and industry leaders implementing financial capital development activities to accelerate the growth of the life science industry in California. *Nominee for Biocom Catalyst Award 2022
Jul 2022 - Present
Investor | Venture Capital
Early backer of 2 Nobel Prize -winning technologies and Board Observer at 3 portfolio companies, resulting in improved fund performance at a deep-tech fund w/ ~$1B AUM.*Carolyn Bertozzi, InterVenn Biosciences, Nobel Prize in Chemistry 2022*Jennifer Doudna, Excision Biotherapeutics, Nobel Prize in Chemistry 2020
Nov 2019 - Mar 2022
Investor
*Sourced and led diligence for $60M Series A financing, Feb 2021.Excision develops CRISPR-based therapies to cure viral infectious diseases. Pre-clinical in vivo studies for EBT-101 were the first to demonstrate removal of SIV proviral DNA in non-human primates, indicating potential for the development of a functional cure for HIV in human patients.
Feb 2021 - Feb 2022
Investor & Board Observer
*Sourced and led diligence for $34M Series B financing, July 2020*Syndicate member in $201M Series C round led by SoftBank, July 2021InterVenn's AI-enabled mass spectrometry platform unlocks scalable analysis of glycosylated elements from patient blood samples, permitting a new category of disease biomarkers for improved cancer diagnostics and therapeutic.
Jul 2020 - Feb 2022
Board Observer
ImmunoScape's platform combines mass cytometry, single cell sequencing, and bioinformatics to perform high-dimensional profiling of T-cell populations for development of immunotherapies and therapeutic vaccines.
Dec 2019 - Feb 2022
Board Observer
BioSkryb is commercializing a new method for whole genome amplification, PTA, which accurately recovers more than 95% of the genomes of single cells and greatly improves the ability to detect rare mutations.
Dec 2019 - Feb 2022
Associate | Patent Prosecution & Strategy For Startups
Directed interactions with executive and engineering leads of venture-backed technology startups to build valuable patent portfolios and develop IP strategy; Identified key features of inventions to craft comprehensive and high-quality patent applications in U.S. and foreign jurisdictions; Motivated and fostered new client relationships sourced from broad.
Jan 2018 - Sep 2018
Doctoral Research Fellow | Next-Generation Neural Interfaces
Spearheaded an interdisciplinary research program focusing on flexible bioelectronic neural interfaces with applications in brain-mapping, prosthetics, and neuromodulation. Projects included: brain-polymer hybrids (CLARITY), electronic skin, and genetically-targeted polymer synthesis in active mammalian neurons. Co-author of two publications in Science.
Jun 2012 - Dec 2017
Research Scientist | Physical Principles Governing Neural Stimulation And Drug Delivery
Engaged in several collaborative research efforts between UC Berkeley Engineering and UCSF Neurosurgery. Projects include: uEcoG arrays in rodents and cyborg beetles; Peptide-polymer conjugate micelles for delivery of doxorubicin to brain tumors; Thin films for delivery of XAV939 to optic nerve
Aug 2011 - May 2012
Research Scientist | Prosthetic Cornea
Devised a photolithographic method to precisely tune the curvature of interpenetrating hydrogel networks for a prosthetic cornea. Synthesis and characterization of 3D PEG/PAA hydrogel networks under various photolithographic patterning conditions significantly decrease manufacturing costs of curved polymeric lenses.Co-Inventor, patent application.
Jan 2009 - Jun 2011
Research Scientist | High-Throughput Gene Sequencing Of Individual Organism'S Immune Repertoire
In college, worked with Dr. Stephen Quake on one of the first demonstrations of high-throughput sequencing to determine the complete diversity of of an individual organism's antibody repertoire. We discovered that the abundance distributions of both the VDJ repertoire and antibody heavy-chain diversity were similar between individuals, that VDJ usage is.
May 2008 - Sep 2008
Research Assistant | Foundations Of Applied Gene Editing & Characterization
In high school, developed lines of genetically-modified insects using early 2000s gene editing techniques to engineer mosquitos from carrying transmissible disease (e.g., malaria, yellow fever). This work led to my first publication. Arensburger P, Hice RH, Zhou L, Smith RC, Tom AC, Wright JA, Knapp J, O'Brochta DA, Craig NL, Atkinson PW. Phylogenetic and.
2005 - 2006
~1 yr
5 education records
Ariane Tom, Phd education
Doctor Of Philosophy (Ph.D.), Bioengineering
Stanford University
Master Of Science (M.S.), Bioengineering
Stanford University
B.S., Materials Science & Engineering
Stanford University
Science & Technology Policy Fellowship - Washington, Dc, Strategic Analyst At Doe Office Of Energy Efficiency And Renewable Energy (Eere)
Stanford University
Certificate, Finance And Financial Management Services
Harvard Business School Online
FAQ
Frequently asked questions about Ariane Tom, Phd
Quick answers generated from the profile data available on this page.
What company does Ariane Tom, Phd work for?
Ariane Tom, Phd works for Kaleida Capital.
What is Ariane Tom, Phd's role at Kaleida Capital?
Ariane Tom, Phd is listed as Founder and Managing Director at Kaleida Capital.
What is Ariane Tom, Phd's email address?
AeroLeads has found 1 work email signal at @kaleidacapital.com for Ariane Tom, Phd at Kaleida Capital.
What is Ariane Tom, Phd's phone number?
AeroLeads has found 1 phone signal(s) with area code 888 for Ariane Tom, Phd at Kaleida Capital.
Where is Ariane Tom, Phd based?
Ariane Tom, Phd is based in San Diego, California, United States while working with Kaleida Capital.
What companies has Ariane Tom, Phd worked for?
Ariane Tom, Phd has worked for Kaleida Capital, Anthropic, Manifest Technologies, Milken Institute, and One Mind.
How can I contact Ariane Tom, Phd?
You can use AeroLeads to view verified contact signals for Ariane Tom, Phd at Kaleida Capital, including work email, phone, and LinkedIn data when available.
What schools did Ariane Tom, Phd attend?
Ariane Tom, Phd holds Doctor Of Philosophy (Ph.D.), Bioengineering from Stanford University.
What skills is Ariane Tom, Phd known for?
Ariane Tom, Phd is listed with skills including Biotechnology, Nanomaterials, Chemical Engineering, Bioelectronics, Organic Semiconductors, Characterization, Materials Characterization, and Life Sciences.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial